Drug Associated Toxic Nephropathy Identified in the United States Food and Drug Administration Adverse Event Reporting System Database

被引:0
|
作者
Balaha, Mohamed F. [1 ]
Ahmed, Nehad J. [1 ]
Khafagy, El Sayed A. [2 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Alkharj, Saudi Arabia
[2] Prince Sattam Bin Abdulaziz Univ, Dept Pharmaceut, Coll Pharm, Alkharj, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2022年 / 41卷 / 11期
关键词
adverse event; nephrotoxic drug; nephrotoxicity; reporting; ACUTE-RENAL-FAILURE; NEPHROTOXICITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acute kidney injury has a complex pathophysiology, but the main causes are sepsis, ischemia, and nephrotoxicity. Drugs cause about 20% of nephrotoxicity. The aim of this study was to describe reports of drug-associated toxic nephropathy. The FDA Adverse Event Reporting System was used to conduct a retrospective, descriptive analysis of all reported drug-associated nephrotoxicity. A total of 7924 reports of drug-associated toxic nephropathy were submitted to the FDA Adverse Event Reporting System. The most reported medications that were associated with toxic nephropathy were tacrolimus (11.21%), cyclosporine (11.13%), vancomycin (9.58%), cisplatin (6.51%), methotrexate (5.04%), mycophenolate mofetil (4.85%), cyclophosphamide (4.76%), prednisone (3.92%), etoposide (3.79%), and tenofovir disoproxil fumarate (3.15%). Immunosuppressive drugs, antibacterial agents, antineoplastic therapies, and antiviral drugs are among the most regularly used medications that have been recognized as potentially nephrotoxic. Early detection can be achieved through careful observation and monitoring of renal function, while fast discontinuation of toxic medical treatment is necessary to prevent additional damage and, in many cases, entirely reverse renal injury.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Trends in copper versus hormonal intrauterine device breakage reporting within the United States? Food and Drug Administration Adverse Event Reporting System
    Latack, Kyle R.
    Nguyen, Brian T.
    CONTRACEPTION, 2023, 118
  • [42] Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database
    Cassard, Lydia
    Mitchell, Jameson
    Piliang, ana Melissa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (03) : 589 - 589
  • [43] Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system
    Kamath, Ashwin
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [44] Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database
    Le, Gia Han
    Wong, Sabrina
    Kwan, Angela T. H.
    Rosenblat, Joshua D.
    Mansur, Rodrigo B.
    Teopiz, Kayla M.
    Ho, Roger
    Rhee, Taeho Greg
    Vinberg, Maj
    Cao, Bing
    Liao, Sonya
    Mcintyre, Roger S.
    CNS SPECTRUMS, 2024, 29 (06) : 682 - 696
  • [45] Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Emily E. Leppien
    Bennett J. Doughty
    Karyssa L. Hurd
    Keira N. Strong
    Brian J. Piper
    Kenneth L. McCall
    Clinical Drug Investigation, 2023, 43 : 393 - 399
  • [46] Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib
    Liu, Zhijing
    Wu, Dongzhi
    Ke, Chengjie
    Nian, Qichun
    Chen, Yan
    Huang, Yaping
    Chen, Maohua
    ONCOLOGY, 2024, 102 (12) : 1084 - 1096
  • [47] Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Leppien, Emily E.
    Doughty, Bennett J.
    Hurd, Karyssa L.
    Strong, Keira N.
    Piper, Brian J.
    McCall, Kenneth L.
    CLINICAL DRUG INVESTIGATION, 2023, 43 (06) : 393 - 399
  • [48] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Thomas J. Moore
    Richard L. Morrow
    Colin R. Dormuth
    Barbara Mintzes
    Pharmaceutical Medicine, 2020, 34 : 135 - 140
  • [49] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Moore, Thomas J.
    Morrow, Richard L.
    Dormuth, Colin R.
    Mintzes, Barbara
    PHARMACEUTICAL MEDICINE, 2020, 34 (02) : 135 - 140
  • [50] Bevacizumab-Associated Pancreatitis: Cases Reported to the Adverse Event Reporting System of the Food and Drug Administration
    Parikh, Malav
    Ehrenpreis, Eli
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S64 - S64